Publication: CBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cells
cris.virtual.author-orcid | 0009-0006-4376-7959 | |
cris.virtual.author-orcid | 0000-0003-4930-1886 | |
cris.virtualsource.author-orcid | a76d6b99-eb7a-42b8-9e78-8a5b78c76aed | |
cris.virtualsource.author-orcid | 505afc62-d641-464b-a8e0-5ad727ed9d82 | |
cris.virtualsource.author-orcid | ab0421a7-802d-4df5-adc1-edf735f69143 | |
cris.virtualsource.author-orcid | e5e2ea05-f556-4f8d-a2cd-7db4c65dd364 | |
cris.virtualsource.author-orcid | 902f94f2-f23b-485b-b431-b84c91df0d19 | |
cris.virtualsource.author-orcid | 8ecd9cb4-6581-4dbe-9f46-87443cd81f0c | |
cris.virtualsource.author-orcid | 89e49780-414b-4f63-a9ef-037fb28a32b2 | |
dc.contributor.author | Kappel, Sven | |
dc.contributor.author | Melek, Korollus | |
dc.contributor.author | Ross-Kaschitza, Daniela | |
dc.contributor.author | Hauert, Barbara | |
dc.contributor.author | Gerber, Christian Elias | |
dc.contributor.author | Lochner, Martin | |
dc.contributor.author | Peinelt, Christine | |
dc.date.accessioned | 2024-10-26T17:31:36Z | |
dc.date.available | 2024-10-26T17:31:36Z | |
dc.date.issued | 2024-03-07 | |
dc.description.abstract | Introduction: Upon activation at low pH, TMEM206 conducts Cl− ions across plasma and vesicular membranes. In a (patho)physiological context, TMEM206 was reported to contribute to acid-induced cell death in neurons, kidney and cervical epithelial cells. We investigated the role of TMEM206 in acidinduced cell death in colorectal cancer cells. In addition, we studied CBA as a new small molecule inhibitor for TMEM206. Methods: The role of TMEM206 in acid-induced cell death was studied with CRISPR/Cas9-mediated knockout and FACS analysis. The pharmacology of TMEM206 was determined with the patch clamp technique. Results: In colorectal cancer cells, TMEM206 is not a critical mediator of acidinduced cell death. CBA is a small molecule inhibitor of TMEM206 (IC50 = 9.55 μM) at low pH, at pH 6.0 inhibition is limited. Conclusion: CBA demonstrates effective and specific inhibition of TMEM206; however, its inhibitory efficacy is limited at pH 6.0. Despite this limitation, CBA is a potent inhibitor for functional studies at pH 4.5 and may be a promising scaffold for the development of future TMEM206 inhibitors. | |
dc.description.numberOfPages | 9 | |
dc.description.sponsorship | Institut für Biochemie und Molekulare Medizin (IBMM) | |
dc.identifier.doi | 10.48350/194042 | |
dc.identifier.pmid | 38515848 | |
dc.identifier.publisherDOI | 10.3389/fphar.2024.1369513 | |
dc.identifier.uri | https://boris-portal.unibe.ch/handle/20.500.12422/175354 | |
dc.language.iso | en | |
dc.publisher | Frontiers | |
dc.relation.ispartof | Frontiers in Pharmacology | |
dc.relation.issn | 1663-9812 | |
dc.relation.organization | DCD5A442BCD9E17DE0405C82790C4DE2 | |
dc.relation.school | DCD5A442C27BE17DE0405C82790C4DE2 | |
dc.subject.ddc | 500 - Science::570 - Life sciences; biology | |
dc.subject.ddc | 600 - Technology::610 - Medicine & health | |
dc.subject.ddc | 500 - Science::540 - Chemistry | |
dc.title | CBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cells | |
dc.type | article | |
dspace.entity.type | Publication | |
dspace.file.type | text | |
oaire.citation.volume | 15 | |
oairecerif.author.affiliation | Institut für Biochemie und Molekulare Medizin (IBMM) | |
oairecerif.author.affiliation | Institut für Biochemie und Molekulare Medizin (IBMM) | |
oairecerif.author.affiliation | Institut für Biochemie und Molekulare Medizin (IBMM) | |
oairecerif.author.affiliation | Institut für Biochemie und Molekulare Medizin (IBMM) | |
oairecerif.author.affiliation | Institut für Biochemie und Molekulare Medizin (IBMM) | |
oairecerif.author.affiliation | Institut für Biochemie und Molekulare Medizin (IBMM) | |
oairecerif.author.affiliation | Institut für Biochemie und Molekulare Medizin (IBMM) | |
oairecerif.author.affiliation2 | IBMM Gruppe Peinelt | |
oairecerif.author.affiliation2 | IBMM Gruppe Peinelt | |
oairecerif.author.affiliation2 | IBMM Gruppe Peinelt | |
oairecerif.author.affiliation2 | IBMM Gruppe Peinelt | |
oairecerif.author.affiliation2 | IBMM Gruppe Lochner | |
oairecerif.author.affiliation2 | IBMM Gruppe Lochner | |
oairecerif.author.affiliation2 | IBMM Gruppe Peinelt | |
oairecerif.identifier.url | https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1369513/full | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.date.licenseChanged | 2024-03-08 09:48:15 | |
unibe.description.ispublished | pub | |
unibe.eprints.legacyId | 194042 | |
unibe.refereed | TRUE | |
unibe.subtype.article | journal |
Files
Original bundle
1 - 1 of 1
- Name:
- 2024_Kappel_Front_Pharmacol.pdf
- Size:
- 1.92 MB
- Format:
- Adobe Portable Document Format
- File Type:
- text
- License:
- https://creativecommons.org/licenses/by/4.0
- Content:
- published